Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
Key facts
- Where
- Dallas, Daytona Beach, Hialeah, Knoxville, Lexington, Madison, Maitland, Montclair, and Phoenix, United StatesSee the 9 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07908316, who can take part
Where in United States
- Fortrea Clinical Research Unit - DallasDallas, United StatesTaking people
- Fortrea Clinical Research Unit - Daytona BeachDaytona Beach, United StatesTaking people
- AGA Clinical TrialsHialeah, United StatesTaking people
- Alliance for Multispecialty Research KnoxvilleKnoxville, United StatesTaking people
- The Alliance for Multispecialty Research - LexingtonLexington, United StatesTaking people
- Fortrea Clinical Research Unit Inc. - MadisonMadison, United StatesTaking people
- K2 Medical Research ORLANDOMaitland, United StatesTaking people
- Catalina Research Institute LLC (CRI) - MontclairMontclair, United StatesTaking people
- Arizona Research CenterPhoenix, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amgen
- Trial code
- NCT07908316
- Record updated
- 2 November 2026
- Original description
The primary purpose of the study is to assess the pharmacokinetics of maridebart cafraglutode after switching from weekly GLP-1RA in participants living with overweight or obesity.Read full original descriptionShow less
A Phase 1, Randomized, Double-blind, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Maridebart Cafraglutide After Switching From Glucagon-like Peptide-1 Receptor Agonists in Participants Living With Overweight or Obesity
The primary purpose of the study is to assess the pharmacokinetics of maridebart cafraglutode after switching from weekly GLP-1RA in participants living with overweight or obesity.
Inclusion: 18 to 70 years of age; Body Mass Index (BMI) ≥ 25 at screening; BMI ≥ 23 for Asian participants at screening; Stable body weight (approximately 5% or less gain or loss) during the 4-week run-in period, unless the study doctor determines otherwise; Stable dose of weekly GLP-1RA; Stable gastrointestinal (GI) tolerability; Contraception for females; Stable for 3 months if obstructive sleep apnea (OSA), hypertension, hyperlipidemia, and/or hypothyroidism; Willingness to follow trial procedures for the duration of the trial.
Exclusion: Surgery for obesity in the last 6 months; Previous participation in Maridebart cafraglutide trial; Alcohol or drug abuse; Type 1/Type 2 diabetes mellitus (DM); Obesity induced by other endocrine disorder (ex: Cushing's syndrome); History of malignancy in the last 5 tears except for nonmelanoma skin cancers, cervical, or breast ductal carcinoma in situ; Uncontrolled thyroid disease; Heart attack within 3 months; History of ischemic optic neuropathy; Positive HIV or certain positive Hepatitis B or hepatitis C; Acute \& chronic pancreatitis within 1 year; Gastroparesis or gastric outlet obstruction; Current use of compounded weekly GLP-1RA; Pregnancy, breastfeeding, or planning to breastfeed.